See more : Accenture plc (0Y0Y.L) Income Statement Analysis – Financial Results
Complete financial analysis of Galecto, Inc. (GLTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galecto, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Firefinch Limited (EEYMF) Income Statement Analysis – Financial Results
- TCL Technology Group Corporation (000100.SZ) Income Statement Analysis – Financial Results
- Quanta Computer Inc. (QUCCF) Income Statement Analysis – Financial Results
- Tungtex (Holdings) Company Limited (0518.HK) Income Statement Analysis – Financial Results
- Morefield Group N.V. (MORE.AS) Income Statement Analysis – Financial Results
Galecto, Inc. (GLTO)
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 0.00 |
| Gross Profit | -830.00K | -490.00K | -441.00K | -188.00K | -111.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.77M | 48.21M | 38.49M | 24.63M | 36.53M | 10.09M |
| General & Administrative | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Other Expenses | 3.45M | 0.00 | 0.00 | 0.00 | 1.91M | -479.00K |
| Operating Expenses | 35.63M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Cost & Expenses | 36.46M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Interest Income | 1.69M | 722.00K | 156.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 417.00K | 0.00 | 0.00 | 0.00 | 2.97M |
| Depreciation & Amortization | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 12.91K |
| EBITDA | -37.52M | -61.13M | -51.31M | -34.65M | -36.40M | -12.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39.91M | -61.21M | -52.23M | -33.64M | -38.97M | -12.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.56M | -417.00K | 475.00K | -1.20M | 2.46M | -2.96M |
| Income Before Tax | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 417.00K | -475.00K | 1.20M | 1.91M | 2.48M |
| Net Income | -38.35M | -62.04M | -51.28M | -36.04M | -38.42M | -15.87M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| EPS Diluted | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| Weighted Avg Shares Out | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
Galecto to Present at the Upcoming Jefferies Healthcare Conference
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D. will...
Galecto to Present Two Posters at AACR Annual Meeting 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present two posters at...
Orbimed Advisors Now Owns 10.5% of Galecto
Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from...
Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022
BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a live conference call and webcast at...
Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming H.C. Wainwright's 24th...
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting
Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified
Galecto to Present at Upcoming Investor Conferences
BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Galecto's management team will be presenting virtually at the Credit...
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company's Chief Executive Officer, will be presenting...
Source: https://incomestatements.info
Category: Stock Reports